6:18 PM
 | 
Jan 29, 2014
 |  BC Extra  |  Company News

Vertex gets breakthrough for VX-661/Kalydeco combo

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported 4Q13 and 2013 financial results late Wednesday and disclosed that FDA granted breakthrough therapy designation for VX-661 in combination with cystic fibrosis (CF) drug Kalydeco ivacaftor to treat CF...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >